This brand name is authorized in United States. It is also authorized in Australia, Austria, Brazil, Canada, Croatia, Cyprus, Ecuador, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Italy, Lithuania, Netherlands, New Zealand, Poland, Romania, Singapore, Spain, Turkey, UK.
The drug MAVENCLAD contains one active pharmaceutical ingredient (API):
1
|
UNII
47M74X9YT5 - CLADRIBINE
|
|
Cladribine is a nucleoside analogue of deoxyadenosine. In resting cells cladribine causes DNA single-strand breaks, rapid nicotinamide adenine dinucleotide consumption, ATP depletion and cell death. |
|
Below package inserts are available for further reading:
| Document | Type | Information Source | |
|---|---|---|---|
| MAVENCLAD Tablet | MPI, EU: SmPC | European Medicines Agency (EU) |
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| L01BB04 | Cladribine | L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01B Antimetabolites → L01BB Purine analogues |
| L04AA40 | L Antineoplastic and immunomodulating agents → L04 Immunosuppressants → L04A Immunosuppressants → L04AA Selective immunosuppressants | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| AU | Pharmaceutical Benefits Scheme | 11603Q, 11604R, 11611D |
| BR | Câmara de Regulação do Mercado de Medicamentos | 525420020051407, 525420020051507, 525420020051607 |
| CA | Health Products and Food Branch | 02470179 |
| EC | Agencia Nacional de Regulación, Control y Vigilancia Sanitaria | 4683-MEE-0419 |
| EE | Ravimiamet | 1752443, 1752454, 1752465, 1752476, 1752487, 1752498 |
| ES | Centro de información online de medicamentos de la AEMPS | 1171212001 |
| FI | Lääkealan turvallisuus- ja kehittämiskeskus | 130242, 137721, 155121 |
| FR | Base de données publique des médicaments | 65820786 |
| GB | Medicines & Healthcare Products Regulatory Agency | 347911, 347912, 347913 |
| HK | Department of Health Drug Office | 65910 |
| IE | Health Products Regulatory Authority | 88966, 88967, 88968 |
| IL | מִשְׂרַד הַבְּרִיאוּת | 8148, 8149, 8150 |
| IT | Agenzia del Farmaco | 045615010, 045615022, 045615034, 045615046, 045615059, 045615061 |
| LT | Valstybinė vaistų kontrolės tarnyba | 1083745, 1083746, 1083747, 1083748, 1083749, 1083750 |
| NZ | Medicines and Medical Devices Safety Authority | 20042 |
| PL | Rejestru Produktów Leczniczych | 100393522 |
| RO | Agenția Națională a Medicamentului și a Dispozitivelor Medicale | W64663001, W64663002, W64663003, W64663004, W64663005, W64663006 |
| SG | Health Sciences Authority | 15691P |
| TR | İlaç ve Tıbbi Cihaz Kurumu | 8699808090409, 8699808090416, 8699808090423, 8699808090430, 8699808090447, 8699808090454 |
| US | FDA, National Drug Code | 44087-4000 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.